The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Karolinska Institutet
Study ID
NCT04598750
Status
Recruiting
Apply to this trial

Conditions

  • Bleeding
  • Neonatal Thrombocytopenia

Eligibility Criteria

Sex
ALL
Age
1 Day - N/A
Healthy Volunteers
Not accepted

Study Details

This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.

Key Dates

Start date
Jun 15, 2021
Status verified
Oct 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
250 participants (estimated)

Primary Outcome Measure

NeoBAT score [ Time Frame: 24 hours ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215
Martha Sola-Visner, MD
[email protected]
Boston Children's HospitalBostonMassachusetts02115
Martha Sola-Visner, MD
[email protected]
Intermountain Medical CenterMurrayUtah84107
Robert Christensen, MD
[email protected]
Utah Valley HospitalProvoUtah84604
Robert Christensen, MD
[email protected]

Find similar trials in Boston, MA

By research site
Beth Israel Deaconess Medical Center· Boston, MABoston Children's Hospital· Boston, MAIntermountain Medical Center· Murray, UTUtah Valley Hospital· Provo, UT

Related Studies